Kosiborod, Mikhail <br/><br/>
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.  [electronic resource] 

 -  Diabetes, obesity & metabolism  08 2018 
 - 1983-1987 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.13299  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cohort Studies<br/>Comparative Effectiveness Research<br/>Diabetes Mellitus, Type 2--complications<br/>Diabetic Angiopathies--epidemiology<br/>Diabetic Cardiomyopathies--epidemiology<br/>Diabetic Neuropathies--epidemiology<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Insurance, Health<br/>Intention to Treat Analysis<br/>Male<br/>Medical Records<br/>Middle Aged<br/>Myocardial Infarction--complications<br/>Prevalence<br/>Propensity Score<br/>Proportional Hazards Models<br/>Risk<br/>Scandinavian and Nordic Countries--epidemiology<br/>Sodium-Glucose Transporter 2 Inhibitors--adverse effects<br/>Stroke--complications<br/>United States--epidemiology